scorecardresearch
Friday, August 29, 2025
TopicObesity

Topic: Obesity

SubscriberWrites: Comforts come with costs

The sedentary lifestyle and overdependence on doorstep services made the urbanites lazy and lethargic.

Childhood obesity is rising globally. It can have lifelong implications

On the surface, problems with weight may seem simple – the body stores excess energy from food as fat. But the reality is that obesity is a complex chronic disease which can be caused by many interlinked factors.

Tackling mental health problems and obesity key to India’s growth — Economic Survey

Survey emphasises a balanced and diverse diet to deal with the burgeoning obesity problem. It also recognises mental health as a principal factor in individual & national development.

Blockbuster diabetes & obesity drug gets nod for India launch but may be available only next year

Tirzepatide is a type 2 diabetes and obesity drug sold by US firm Eli Lilly under the brand names Mounjaro and Zepbound. It may take around 6 months for it to be launched in India.

Govt panel urges regulator to approve import of American drug for diabetes, obesity

Lilly's Mounjaro is a popular choice for weight loss. Mounjaro is expected to launch in India in India in 2025.

82.5 mn Indians were ‘obese’ in 2022, shows Lancet study. Doctors, nutritionists say ‘tip of iceberg’

Study, conducted by NCD Risk Factor Collaboration & WHO, shows that nearly 880 million adults globally living with obesity in 2022 — 4.5 times higher than the number recorded in 1990.

Diabetes drug semaglutide offers hope beyond obesity management — kidney, heart & liver health

Study by Australian & Canadian scientists, published in Kidney International, finds that drug may be effective at reducing inflammation — lowering risk of heart & kidney disease.

Social isolation and loneliness are as fatal as smoking and obesity

Social isolation experienced in childhood can foreshadow health issues decades later.

Tirzepatide, another diabetes drug cleared for weight loss in US, yet to get regulator nod in India

In clinical trials, tirzepatide by Eli Lilly has shown to reduce body weight by up to 22.5 percent, on average, after about 72 weeks, according to the company.

Desperate Indians want Ozempic on prescription. Huge shift from traditional drugs, say doctors

Given the hype, semaglutide is gaining traction across India with the requests pouring in – more so in private, luxury clinics.

On Camera

Mohan Bhagwat’s U-turn on ‘retire at 75’ is a Hindu succession problem

RSS chief Mohan Bhagwat has backtracked on his retirement rules. The ‘75-year rule’ was applied selectively to sideline some leaders, but it doesn’t apply to the top brass.

Easy loans, uneasy ‘debt traps’. Women harassed by private lenders ask ‘who will restore lost dignity?’

A public meeting, where the women voiced their protest, took place this month in Delhi, grounded on the findings of an AIDWA survey, covering 9,000 women borrowers.

Post-Sindoor, joint doctrine tasks Special Forces with fighting info warfare & countering propaganda

Joint Doctrine for Special Forces Operations, released Wednesday, also outlines plans for the future expansion of AFSOD and the creation of Joint Service Training Institutes.

That Oval Office picture for ages deserves closer Indian reading, with a geopolitical lens

Putin sees this as a victory. Europeans have decided to deal with Trump on his terms for the sake of the larger Western alliance. We look at the lessons for us in India.